Edition:
United Kingdom

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

26.35USD
18 Oct 2018
Change (% chg)

$-0.77 (-2.84%)
Prev Close
$27.12
Open
$27.04
Day's High
$27.10
Day's Low
$25.98
Volume
19,304
Avg. Vol
--
52-wk High
$32.25
52-wk Low
$17.35

Summary

Name Age Since Current Position

Norbert Riedel

60 President, Chief Executive Officer, Director

Joseph Moskal

Chief Scientific Officer

Patricia Adams

Vice President - Human Resources and Administration

Ashish Khanna

Chief Business Officer

Torsten Madsen

Chief Medical Officer

Biographies

Name Description

Norbert Riedel

Dr. Norbert G. Riedel is President, Chief Executive Officer, Director of the company. Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017. Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine and, prior to moving into industry, was an associate professor of medicine at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.

Joseph Moskal

Dr. Joseph R. Moskal Ph.D. is Chief Scientific Officer of the company. Dr. Moskal is chief scientific officer of Aptinyx. He founded Naurex and served as its chief scientific officer until the company was acquired by Allergan. He is also distinguished professor of biomedical engineering at Northwestern University and director of the university’s Falk Center for Molecular Therapeutics. Dr. Moskal previously served as assistant professor and director of the neurosurgery laboratories at the Albert Einstein College of Medicine. Earlier, he was a staff fellow at the National Institutes of Health. Dr. Moskal is well known for his research on the NMDA receptor. He received a B.S. and a Ph.D. from the University of Notre Dame.

Patricia Adams

Ms. Patricia Adams is Vice President - Human Resources and Administration of the Company. Ms. Adams is vice president of human resources and administration at Aptinyx. She has over 24 years of experience in the healthcare industry, which includes 15 years in human resources. Previously, Ms. Adams was vice president of human resources at Naurex. Prior to joining Naurex, she served as senior director of human resources for Durata Therapeutics where she managed HR planning and operations in support of the commercial launch of Dalvance®. Ms. Adams has also led human resources functions at SagePath Medical, BioSante Pharmaceuticals, Lundbeck Inc., and Takeda Pharmaceuticals North America. Ms. Adams earned a B.A. in psychology from Columbia College and an M.S. in human resources from Loyola University Chicago.

Ashish Khanna

Mr. Ashish Khanna is Chief Business Officer of the Company. Mr. Khanna is chief business officer of Aptinyx, with responsibilities that include finance, corporate and business development, alliance management, legal, and communications. He was previously vice president of corporate development at Naurex and managed its financing and transaction efforts, culminating in the company’s acquisition by Allergan. Prior to Naurex, Mr. Khanna served as director of business development at Vanda Pharmaceuticals. He was formerly a member of the cardiology strategic marketing team at Cordis Corporation, a Johnson & Johnson company. Earlier, Mr. Khanna was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (now Capgemini). He serves on the board of directors of the Illinois Biotechnology Innovation Organization. Mr. Khanna received a B.S. in finance and B.A.S. in systems engineering from the University of Pennsylvania, as well as an M.B.A. from the Wharton School.

Torsten Madsen

Dr. Torsten M. Madsen is Chief Medical Officer of the Company. He joined the management team of Naurex after serving as an observer on the company’s board of directors. He was previously chief medical officer and vice president of US drug development at Lundbeck. Prior to this, Dr. Madsen was divisional director of international clinical research in mood and anxiety disorders at Lundbeck. Before joining Lundbeck, Dr. Madsen was a resident physician in psychiatry at Aarhus University Hospital in Denmark. Dr. Madsen received an M.D. and a Ph.D. from Copenhagen University and worked as a postdoctoral associate in the department of molecular psychiatry at Yale University.

Basic Compensation

Options Compensation